Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027
Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A…
Read More
After Nvidia’s Rally: Is It Time to Invest in Asian Chip Stocks?
Nvidia, a top-tier company in the world of graphics processing units (GPUs), has recently enjoyed a meteoric rise in its…
Read More
Private equity: Here’s what it is, and how the sector can be a blessing and a curse to retail investors
You may have heard of the term ‘Private Equity’ (PE) before. You may have seen a company been taken over…
Read More